Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import.

Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, Than ME, Mackenzie IR, Capell A, Schmid B, Neumann M, Haass C.

EMBO J. 2010 Aug 18;29(16):2841-57. doi: 10.1038/emboj.2010.143.

2.

Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS.

Dormann D, Madl T, Valori CF, Bentmann E, Tahirovic S, Abou-Ajram C, Kremmer E, Ansorge O, Mackenzie IR, Neumann M, Haass C.

EMBO J. 2012 Nov 14;31(22):4258-75. doi: 10.1038/emboj.2012.261.

3.
4.

FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.

Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, Roeber S, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ang LC, Bilbao J, Rademakers R, Haass C, Mackenzie IR.

Brain. 2011 Sep;134(Pt 9):2595-609. doi: 10.1093/brain/awr201.

5.

Nuclear import factor transportin and arginine methyltransferase 1 modify FUS neurotoxicity in Drosophila.

Jäckel S, Summerer AK, Thömmes CM, Pan X, Voigt A, Schulz JB, Rasse TM, Dormann D, Haass C, Kahle PJ.

Neurobiol Dis. 2015 Feb;74:76-88. doi: 10.1016/j.nbd.2014.11.003.

PMID:
25447237
6.

Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.

Neumann M, Valori CF, Ansorge O, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ishihara K, Ang LC, Bilbao JM, Mackenzie IR.

Acta Neuropathol. 2012 Nov;124(5):705-16. doi: 10.1007/s00401-012-1020-6.

PMID:
22842875
7.
8.

Nuclear localization sequence of FUS and induction of stress granules by ALS mutants.

Gal J, Zhang J, Kwinter DM, Zhai J, Jia H, Jia J, Zhu H.

Neurobiol Aging. 2011 Dec;32(12):2323.e27-40. doi: 10.1016/j.neurobiolaging.2010.06.010.

9.

Phosphorylation of C-terminal tyrosine residue 526 in FUS impairs its nuclear import.

Darovic S, Prpar Mihevc S, Župunski V, Gunčar G, Štalekar M, Lee YB, Shaw CE, Rogelj B.

J Cell Sci. 2015 Nov 15;128(22):4151-9. doi: 10.1242/jcs.176602.

10.

FUS-NLS/Transportin 1 complex structure provides insights into the nuclear targeting mechanism of FUS and the implications in ALS.

Niu C, Zhang J, Gao F, Yang L, Jia M, Zhu H, Gong W.

PLoS One. 2012;7(10):e47056. doi: 10.1371/journal.pone.0047056.

11.

ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules.

Vance C, Scotter EL, Nishimura AL, Troakes C, Mitchell JC, Kathe C, Urwin H, Manser C, Miller CC, Hortobágyi T, Dragunow M, Rogelj B, Shaw CE.

Hum Mol Genet. 2013 Jul 1;22(13):2676-88. doi: 10.1093/hmg/ddt117.

12.

Autophagy regulates amyotrophic lateral sclerosis-linked fused in sarcoma-positive stress granules in neurons.

Ryu HH, Jun MH, Min KJ, Jang DJ, Lee YS, Kim HK, Lee JA.

Neurobiol Aging. 2014 Dec;35(12):2822-31. doi: 10.1016/j.neurobiolaging.2014.07.026.

PMID:
25216585
13.

Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.

Verbeeck C, Deng Q, Dejesus-Hernandez M, Taylor G, Ceballos-Diaz C, Kocerha J, Golde T, Das P, Rademakers R, Dickson DW, Kukar T.

Mol Neurodegener. 2012 Oct 10;7:53. doi: 10.1186/1750-1326-7-53.

14.

Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.

Ito D, Suzuki N.

Neurology. 2011 Oct 25;77(17):1636-43. doi: 10.1212/WNL.0b013e3182343365. Review.

15.

Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration.

Dormann D, Haass C.

Mol Cell Neurosci. 2013 Sep;56:475-86. doi: 10.1016/j.mcn.2013.03.006. Review.

PMID:
23557964
16.

Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).

Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C.

J Biol Chem. 2012 Jun 29;287(27):23079-94. doi: 10.1074/jbc.M111.328757.

17.

TDP-43 and FUS: a nuclear affair.

Dormann D, Haass C.

Trends Neurosci. 2011 Jul;34(7):339-48. doi: 10.1016/j.tins.2011.05.002.

PMID:
21700347
18.

Directly converted patient-specific induced neurons mirror the neuropathology of FUS with disrupted nuclear localization in amyotrophic lateral sclerosis.

Lim SM, Choi WJ, Oh KW, Xue Y, Choi JY, Kim SH, Nahm M, Kim YE, Lee J, Noh MY, Lee S, Hwang S, Ki CS, Fu XD, Kim SH.

Mol Neurodegener. 2016 Jan 22;11:8. doi: 10.1186/s13024-016-0075-6.

19.

FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.

Deng Q, Holler CJ, Taylor G, Hudson KF, Watkins W, Gearing M, Ito D, Murray ME, Dickson DW, Seyfried NT, Kukar T.

J Neurosci. 2014 Jun 4;34(23):7802-13. doi: 10.1523/JNEUROSCI.0172-14.2014.

20.

FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation.

Suzuki N, Kato S, Kato M, Warita H, Mizuno H, Kato M, Shimakura N, Akiyama H, Kobayashi Z, Konno H, Aoki M.

J Neuropathol Exp Neurol. 2012 Sep;71(9):779-88. doi: 10.1097/NEN.0b013e318264f164. Erratum in: J Neuropathol Exp Neurol. 2015 Sep;74(9):945.

Items per page

Supplemental Content

Support Center